Aclaris Therapeutics, Inc. (ACRS) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRS trades at $4.53 with a market cap of $614.52M and a P/E ratio of -7.97. ACRS moved +1.80% today. Year to date, ACRS is +70.94%; over the trailing twelve months it is +235.56%. Its 52-week range spans $1.05 to $5.17. Analyst consensus is strong buy with an average price target of $10.38. Rallies surfaces ACRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ACRS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ACRS recently traded at $4.53. Market cap is $614.52M. P/E ratio is -7.97. Revenue is $8.37M.
| Metric | Value |
|---|---|
| Price | $4.53 |
| Market Cap | $614.52M |
| P/E Ratio | -7.97 |
| EPS | $-0.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.17 |
| 52-Week Low | $1.05 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.37M |
| Net Income | $-69.66M |
| Gross Margin | 76.34% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.83M | $-64.92M | $-0.53 |
| 2024 | $18.72M | $-132.06M | $-1.71 |
| 2023 | $31.25M | $-88.48M | $-1.27 |
| 2022 | $29.75M | $-86.91M | $-1.33 |
8 analysts cover ACRS: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.38.